Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Oklahoma Healthcare Wire.
Press releases published on June 12, 2025
スプリング・バイオ・ソリューション (Spring Bio Solution) 、パラグラフIV証明書を伴う申請 (Para IV Filing) およびファースト・トゥ・ファイル機会を解析するNCEグリッド (NCE Grid) を発表
GlobeNewswire
·
June 12, 2025
ニュージャージー州サマセット発, June 12, 2025 (GLOBE NEWSWIRE) -- コンパレータ調達および治験薬供給のグローバルリーダーであるスプリング・バイオ・ソリューションは、世界初の無料NCE-1インテリジェンス・プラットフォームであり、パラグラフIVおよびNCE-1の機会をリアルタイムで解析・集約・可視化することを目的として構築されたNCEグリッドを発表した。 これまで、NCE独占期間の満了およびパラグラフIV …
Spring Bio Solution, 패러그래프 IV 준비와 최초 출원 가능성 해석해주는 NCE Grid 플랫폼 선보여
GlobeNewswire
·
June 12, 2025
미국 뉴저지주 서머싯, June 12, 2025 (GLOBE NEWSWIRE) -- 대조약 공급 및 임상시험 용품 분야의 글로벌 선도 기업 Spring Bio Solution이 세계 최초로 무료 NCE-1 인텔리전스 플랫폼 NCE Grid를 선보였다. 이 플랫폼은 패러그래프 IV 준비와 NCE-1 가능성을 실시간으로 해석하고, 중앙화 및 시각화하기 위해 설계되었다. 지금까지 NCE 독점권 만료일 추적과 패러그래프 IV 증명서 제출은 중앙화된 솔루션이 없어 …
Spring Bio Solution Melancarkan NCE Grid untuk Menyahkod Pemfailan Para IV dan Peluang Pemfail Pertama
GlobeNewswire
·
June 12, 2025
SOMERSET, N.J., June 12, 2025 (GLOBE NEWSWIRE) -- Spring Bio Solution, peneraju global dalam penyumberan komparator dan bekalan percubaan klinikal telah melancarkan NCE Grid, platform risikan NCE-1 percuma pertama di dunia—dibangunkan untuk menyahkod, …
Spring Bio Solution เปิดตัว NCE Grid เพื่อถอดรหัสการยื่นเอกสาร Para IV และโอกาสในการยื่นคำขอครั้งแรก
GlobeNewswire
·
June 12, 2025
ซอเมอร์เซ็ต นิวเจอร์ซีย์, June 12, 2025 (GLOBE NEWSWIRE) -- Spring Bio Solution ผู้นำระดับโลกในด้านการจัดหาตัวเปรียบเทียบและอุปกรณ์การทดลองทางคลินิก ได้เปิดตัว NCE Grid แพลตฟอร์มปัญญาประดิษฐ์ NCE-1 ฟรีแห่งแรกของโลกที่สร้างขึ้นเพื่อถอดรหัส การรวมข้อมูล …
ANI Pharmaceuticals Announces Presentation of New Preclinical Data
GlobeNewswire
·
June 12, 2025
PRINCETON, N.J., June 12, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced new preclinical data on the use of Purified Cortrophin Gel (repository corticotropin injection USP) (Cortrophin Gel) in a mouse …
Counslr Launches in Texas to Increase Access to Mental Health Support for Staff and Students
GlobeNewswire
·
June 12, 2025
NEW YORK, June 12, 2025 (GLOBE NEWSWIRE) -- Counslr, a leading B2B mental health and wellness platform, announced today that it has expanded its footprint into the State of Texas starting with a partnership with Colorado Independent School District (ISD) …
Positive PoNSTEP Study Results Presented at Consortium of Multiple Sclerosis Centers Annual Meeting
GlobeNewswire
·
June 12, 2025
-PoNS Therapeutic Experience Program (PoNSTEP) study demonstrates durable long-term beneficial effects of PoNS Therapy® on gait deficit improvement in people with Multiple Sclerosis- -Presentation of full PoNSTEP study results expanded upon top line data …
I-Mab Regains Compliance with Nasdaq Minimum Bid Price Requirement
GlobeNewswire
·
June 12, 2025
ROCKVILLE, Md., June 12, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (“I-Mab” or the “Company”), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced that on …
Catheter Precision (VTAK) Reports Key Progress for the LockeT Product
GlobeNewswire
·
June 12, 2025
FORT MILL, S.C., June 12, 2025 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (VTAK - NYSE/American), a US based medical device company focused on developing technologically advanced products for the cardiac electrophysiology market announced that LockeT …
BioNTech kündigt strategische Transaktion zur Übernahme von CureVac im Rahmen eines öffentlichen Umtauschangebots an
GlobeNewswire
·
June 12, 2025
Die geplante Übernahme soll die Forschung, Entwicklung, Herstellung und Kommerzialisierung von mRNA-basierten Krebsimmuntherapie-Kandidaten stärken und ist ein weiterer wichtiger Meilenstein in der Umsetzung von BioNTechs Onkologie-Strategie Die Übernahme …
BioNTech Announces Strategic Transaction to Acquire CureVac in Public Exchange Offer
GlobeNewswire
·
June 12, 2025
Acquisition will strengthen the research, development, manufacturing and commercialization of mRNA-based cancer immunotherapy candidates, marking BioNTech’s next key milestone in the execution of its oncology strategy Acquisition of CureVac will complement …
New Prospective Cohort Study Reporting the Efficacy of Arrow™ Chlorhexidine-Impregnated Central Venous Catheters Demonstrates Reduced Infection Rates Among ICU Patients
GlobeNewswire
·
June 12, 2025
WAYNE, Pa., June 12, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced findings from a new multinational study reporting efficacy of Arrow™ Chlorhexidine-Impregnated Central …
MedRisk Welcomes Satish Narayanan as Chief Data Officer, Expanding Data and AI Capabilities
GlobeNewswire
·
June 12, 2025
KING OF PRUSSIA, Pa., June 12, 2025 (GLOBE NEWSWIRE) -- MedRisk, a leading managed care organization focused on improving recovery and cost outcomes in casualty claims, announced today the appointment of Satish Narayanan as Chief Data Officer (“CDO”). In …
Enterome raises $19 million to fund clinical development of its OncoMimics™ immunotherapy to treat Follicular Lymphoma
GlobeNewswire
·
June 12, 2025
Proceeds to fund Phase 1/2 trial of EO2463 OncoMimics™, as a monotherapy or in combination, to treat multiple forms of indolent non-Hodgkin lymphoma (iNHL) $9 million from new investor The Institute for Follicular Lymphoma Innovation (IFLI) $10 million …
Editas Medicine Reports Proprietary Targeted Lipid Nanoparticle Delivery in Non-Human Primates Enables In Vivo HBG1/2 Promoter Editing for Sickle Cell Disease and Beta Thalassemia at the European Hematology Association 2025 Congress in June
GlobeNewswire
·
June 12, 2025
Achieved 58% mean editing at five months after a single dose using high efficiency HSC delivery, demonstrating therapeutically relevant editing levels using a clinically validated strategy. Achievement supports development of a novel, in vivo approach to …
Autolus Therapeutics Presents Long-Term Follow Up from the FELIX Study Demonstrating Obe-Cel's Potential for Long-Term Remission in R/R B-ALL at the 2025 European Hematology Association (EHA) Congress
GlobeNewswire
·
June 12, 2025
Median duration of response in FELIX study now 42.6 months after an additional 11 months of follow up More than half of patients still in remission at 24 months 38% of ongoing responders did not receive any subsequent therapy by month 33 Results suggest a …
Diagonal Therapeutics to Present New Preclinical Data Demonstrating Disease-Modifying Potential of Receptor Clustering Antibody Approach in HHT at EHA 2025 Congress
GlobeNewswire
·
June 12, 2025
Results demonstrate potential of Company’s clustering antibody approach to address key challenges in HHT disease manifestations: restoring ALK1-mediated cellular signaling, preventing and reversing arteriovenous malformations, and preventing HHT-associated …
AB Science announces issuance of a Canadian patent protecting the composition of matter of AB8939, including its use in the treatment of acute myeloid leukemia, with protection until 2036
GlobeNewswire
·
June 12, 2025
PRESS RELEASE AB SCIENCE ANNOUNCES ISSUANCE OF A CANADIAN PATENT PROTECTING THE COMPOSITION OF MATTER OF AB8939, INCLUDING ITS USE IN THE TREATMENT OF ACUTE MYELOID LEUKEMIA (AML), WITH PROTECTION UNTIL 2036 THIS PATENT COMPLETES INTELLECTUAL PROPERTY …
AB Science annonce la délivrance d’un brevet canadien protégeant la composition de matière d’AB8939, y compris son utilisation dans le traitement de la leucémie myéloide aigue, avec une protection jusqu’à 2036
GlobeNewswire
·
June 12, 2025
COMMUNIQUÉ DE PRESSE AB SCIENCE ANNONCE LA DÉLIVRANCE D'UN BREVET CANADIEN PROTÉGEANT LA COMPOSITION DE MATIERE D’AB8939, Y COMPRIS SON UTILISATION DANS LE TRAITEMENT DE LA LEUCÉMIE MYÉLOÏDE AIGUË (LMA), AVEC UNE PROTECTION JUSQU'EN 2036 CE BREVET COMPLÈTE …
Dapirolizumab Pegol Phase 3 Data in SLE Presented at the Annual European Congress of Rheumatology (EULAR) Show Improvement in Fatigue and Reduction in Disease Activity
GlobeNewswire
·
June 12, 2025
Dapirolizumab pegol (DZP) showed efficacy across multiple clinical endpoints in the PHOENYCS GO study, including fatigue and measures of disease activity DZP showed consistent improvements in fatigue, a common and debilitating symptom of systemic lupus …